Searching On:

Disease:

Gene:

ERBB2 (HER2), Gene Amplification

View:
Expand Collapse No disease selected  - General Description
Mass General Hospital Cancer Center treats patients with many cancer types. To learn more about the different cancer types that can be treated at the Cancer Center, please visit the Cancer Center website at the following page: http://www.massgeneral.org/cancer/services/
Expand Collapse ERBB2 (HER2)  - General Description ERBB2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ERBB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells. Extra copies of the ERBB2 (HER2) gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2) protein have also been found in certain tumors. Source: Genetics Home ReferenceERBB2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ERBB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells. Extra copies of the ERBB2 (HER2) gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2) protein have also been found in certain tumors. Source: Genetics Home Reference
CLICK IMAGE FOR MORE INFORMATION
ERBB2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ERBB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells.

Extra copies of the ERBB2 (HER2) gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2) protein have also been found in certain tumors.

Source: Genetics Home Reference
ERBB2, often called HER2, is a gene that provides the code for making a cell surface growth receptor called the ERBB2 (HER2). When certain growth factors (proteins that stimulate cell growth and division) bind to this receptor, they activate a signaling system inside the cell that ultimately promotes diverse functions such as growth, interaction and adhesion between cells, and ability of the cell to migrate within tissues. In some tumors, the activation of HER2 signaling is an important mechanism that drives the disease process. This can occur through HER2 gene amplification (the most common mechanism) or HER2 gene mutation in cancer cells.

Extra copies of the ERBB2 (HER2) gene (gene amplification) have been found in a number of different cancers. This causes the cancer cells to make excess HER2 (overexpression), which in turn, tells the cells to grow and divide in an uncontrolled manner. Genetic mutations (changes in the DNA sequence that codes the ERBB2 (HER2) protein have also been found in certain tumors.

Source: Genetics Home Reference
PubMed ID's
15864276, 9130710, 15457249, 16397024, 18772890, 16843263, 16988931, 22899400
Expand Collapse Gene Amplification  in ERBB2 (HER2)
Genetic alterations in HER2 have been found in several types of cancer. The alterations found in different tumors include gene amplification, in which multiple copies of the HER2 gene are found in cancer cells. Overexpression of HER2 has also been found in some cancers, resulting in a higher level of the ERBB2 (HER2) protein being produced in cells, and therefore a higher level of activity. Other genetic alterations include the insertion of nucleotides in one portion of the gene called exon 20. All of these changes result in ERBB2 (HER2) proteins that cannot be regulated normally by the cell, and the protein sends constant signals to the tumor cells to grow and proliferate.

Testing for gene amplification, exon 20 insertion, and all ERBB2 (HER2) mutations is performed at the Center for Integrated Diagnostics at MGH. Treatment is available at the MGH Cancer Center. In addition, clinical trials are available investigating novel HER2 inhibitors and combination drug strategies.
Genetic alterations in HER2 have been found in several types of cancer. The alterations found in different tumors include gene amplification, in which multiple copies of the HER2 gene are found in cancer cells. Overexpression of HER2 has also been found in some cancers, resulting in a higher level of the ERBB2 (HER2) protein being produced in cells, and therefore a higher level of activity. Other genetic alterations include the insertion of nucleotides in one portion of the gene called exon 20. All of these changes result in ERBB2 (HER2) proteins that cannot be regulated normally by the cell, and the protein sends constant signals to the tumor cells to grow and proliferate.

Testing for gene amplification, exon 20 insertion, and all ERBB2 (HER2) mutations is performed at the Center for Integrated Diagnostics at MGH. Treatment is available at the MGH Cancer Center. In addition, clinical trials are available investigating novel HER2 inhibitors and combination drug strategies.

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (G) - Gene, (M) - Mutation
Trial Status: Showing Results: 1-10 of 12 Per Page:
12Next »
Protocol # Title Location Status Match
NCT01494662 HKI-272 for HER2-Positive Breast Cancer and Brain Metastases HKI-272 for HER2-Positive Breast Cancer and Brain Metastases MGH Open GM
NCT01953926 Neratinib HER Mutation Basket Study (SUMMIT) Neratinib HER Mutation Basket Study (SUMMIT) MGH Open GM
NCT03043313 Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer MGH Open GM
NCT02491099 A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma MGH Open G
NCT02716116 A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC) A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC) MGH Open G
NCT03587740 ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer MGH Open G
NCT03716180 DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC MGH Open G
NCT03095352 Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease MGH Open G
NCT03318939 Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation MGH Open G
NCT02500199 Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors MGH Open G
Trial Status: Showing Results: 1-10 of 12 Per Page:
12Next »

Share with your Physican

Print information for your Physician.

Print information